Ultrashort Nasdaq Biotech Proshares (BIS) 43.90 $BIS Top

New Post Public Reply Private Reply Replies (0) Message Board

Mar 6, 2016 at 2:56 AM

Ultrashort Nasdaq Biotech Proshares (BIS) 43.90 $BIS

Top ETF Stories of February
Zacks Equity Research - ZACKS - Tue Mar 01, 5:03AM CST
Inside the top ETF stories of February that pulled the strings in the investing world throughout the month.
PTF: 36.15 (+0.08), KRE: 38.37 (+0.45), EFZ: 34.64 (-0.23), BIS: 43.90 (+0.49), DTYL: 80.60 (-0.31), IGV: 96.17 (-0.08), SQQQ: 20.69 (-0.02), GLD: 120.54 (-0.19), FXY: 84.94 (-0.24), EUFN: 18.04 (-0.01)

The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, iShares Nasdaq Biotechnology ETF, ProShares UltraShort Nasdaq Biotechnology ETF, Direxion Daily S&P Biotech Bear 3x Shares and ProShares UltraProShort Nasdaq Biotechnology
Zacks Equity Research - Zacks Investment Research - Wed Sep 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, iShares Nasdaq Biotechnology ETF, ProShares UltraShort Nasdaq Biotechnology ETF, Direxion Daily S&P Biotech Bear 3x Shares and ProShares UltraProShort Nasdaq Biotechnology
BIS: 43.90 (+0.49), VRX: 61.31 (-3.58), IBB: 263.13 (-1.11), LABD: 57.97 (-0.93), ZBIO: 37.06 (+0.49)

How to Short Biotechnology Stocks with ETFs
Sweta Killa - Zacks Investment Research - Tue Sep 29, 9:17AM CDT
Here are the three ETF ways to play the bearish trend in the biotech sector.
BIS: 43.90 (+0.49), VRX: 61.31 (-3.58), IBB: 263.13 (-1.11), LABD: 57.97 (-0.93), ZBIO: 37.06 (+0.49)

Guide to Inverse & Leveraged Biotech ETF Investing
Zacks Equity Research - Zacks Investment Research - Fri Sep 25, 11:08AM CDT
Understanding the basics of investing in the inverse and leveraged biotech ETFs, depending on market conditions.
BIS: 43.90 (+0.49), BIB: 42.07 (-0.31), UBIO: 25.04 (-0.28), LABU: 7.37 (+0.13), LABD: 57.97 (-0.93), ZBIO: 37.06 (+0.49)

This Is The Week! Finally!
Chuck Butler - Daily Reckoning - Mon Sep 14, 9:26AM CDT
This post This Is The Week! Finally! appeared first on Daily Reckoning . The week is finally here when the FOMC will make a rate decision. Chuck Butler remains steadfast in his call - read on to see if the markets are on board too... The post ...
BIS: 43.90 (+0.49), IP: 38.73 (+0.42)

What The ECB Will Do
Chuck Butler - Daily Reckoning - Tue Jun 30, 9:35AM CDT
This post What The ECB Will Do appeared first on Daily Reckoning . Chuck Butler explains the breakdown of the Greek referendum vote that will take place this Sunday, plus the euro rallies then sells off, and another week data print from New...
BIS: 43.90 (+0.49)

Two more triple-levered biotech ETFs launch
Seeking Alpha - at Seeking Alpha - Tue Jun 23, 8:22AM CDT

BBP: 24.62 (+0.19), PBE: 38.64 (-0.12), BBC: 19.08 (+0.02), SBIO: 22.37 (+0.02), BIS: 43.90 (+0.49), HQL: 17.97 (+0.15), FBT: 88.37 (+0.55), BIB: 42.07 (-0.31), XBI: 51.94 (+0.22), BBH: 103.52 (-0.23), IBB: 263.13 (-1.11), LABU: 7.37 (+0.13), LABD: 57.97 (-0.93)

Biotech Bio-Hazard
James Stefurak, CFA - at Seeking Alpha - Tue Jun 16, 10:58AM CDT

BIIB: 263.94 (-4.70), BIS: 43.90 (+0.49), GILD: 87.21 (-0.62), IBB: 263.13 (-1.11), AMGN: 145.98 (+0.14), AAPL: 103.01 (+1.51), CELG: 102.51 (-0.22)

Why I'm Shorting Biotech
George Budwell, The Motley Fool - Motley Fool - Sat Jun 13, 12:16PM CDT
Biotech and biopharma have had an incredible run over the past few years. And like many investors, I've been able to crush the broader markets simply by buying and holding top names in the industry like AbbVie , Gilead Sciences , and Isis...
ESRX: 71.69 (-0.71), BIS: 43.90 (+0.49), ISIS: 57.56 (-0.28), GILD: 87.21 (-0.62), MRK: 52.08 (-0.02), IBB: 263.13 (-1.11), ABBV: 56.15 (+0.22), BMY: 64.71 (-0.29), CELG: 102.51 (-0.22)

Intro Guide to Leveraged Biotech ETF Investing - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Tue Jun 09, 11:08AM CDT
A quick discussion of the ways investors can play the biotechnology sector with leverage.
BIS: 43.90 (+0.49), BIB: 42.07 (-0.31), LABU: 7.37 (+0.13), LABD: 57.97 (-0.93)

When Genius Fails Again, Part I
Addison Wiggin - Daily Reckoning - Fri May 22, 3:06PM CDT
This post When Genius Fails Again, Part I appeared first on Daily Reckoning . Addison takes a look behind the curtain during a seminal moment in The Daily Reckoning’s history… The post When Genius Fails Again, Part I appeared first on Daily...
BIS: 43.90 (+0.49)

Hidden Gems In This Market Cycle's Leading Theme
Cam Hui, CFA - Seeking Alpha - Fri May 08, 5:18AM CDT
Philosophical Economics wrote a terrific post yesterday about how the "Winner take all" economy is affecting companies and the competitive environment. He observed that net margins have been elevated in the last few years. Generally, when...
BIS: 43.90 (+0.49), BIB: 42.07 (-0.31), IBB: 263.13 (-1.11)

FDA to hold public meeting on off-label drug promotion
Seeking Alpha - at Seeking Alpha - Thu May 07, 10:13AM CDT

ABT: 39.18 (+0.36), BIB: 42.07 (-0.31), PFE: 29.71 (-0.18), IBB: 263.13 (-1.11), DRGS: 60.10 (-0.69), LLY: 73.60 (+0.35), BMY: 64.71 (-0.29), GSK: 39.14 (-0.04), JNJ: 106.50 (-0.15), BIS: 43.90 (+0.49), AZN: 28.87 (+0.13), MRK: 52.08 (-0.02), ABBV: 56.15 (+0.22), SNY: 39.81 (+0.19), IRY: 46.73 (+0.13), IXJ: 95.56 (-0.08), NVS: 72.20 (-0.75)

Biotechs continue slide
Seeking Alpha - at Seeking Alpha - Wed Apr 29, 11:42AM CDT

BIS: 43.90 (+0.49), BIB: 42.07 (-0.31), IBB: 263.13 (-1.11)

Drug makers getting visability over aggressive pricing practices
Seeking Alpha - at Seeking Alpha - Mon Apr 27, 10:19AM CDT

MNK: 62.15 (-1.44), BIS: 43.90 (+0.49), VRX: 61.31 (-3.58), BIB: 42.07 (-0.31), IBB: 263.13 (-1.11), DRGS: 60.10 (-0.69)

U.S. drug spending rose 13% in 2014
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 6:28AM CDT

BIS: 43.90 (+0.49), BIB: 42.07 (-0.31), IBB: 263.13 (-1.11), DRGS: 60.10 (-0.69), IXJ: 95.56 (-0.08), IRY: 46.73 (+0.13)

Infographic: Developing Economies Graying Faster
The Financialist - at Seeking Alpha - Thu Apr 09, 4:38PM CDT
(click to enlarge) Original post Read comments Read more articles from Seeking Alpha: Our Second Best Performing Stock For First Quarter 2015 - Maiden Holdings, Ltd. Rich Middle Class, Poor Middle Class Why Investors Shouldn't...
BIS: 43.90 (+0.49), BIB: 42.07 (-0.31), IBB: 263.13 (-1.11), DRGS: 60.10 (-0.69), IXJ: 95.56 (-0.08), IRY: 46.73 (+0.13)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kroger, Imprint Team Up for AI-Driven Mastercard

Kroger Teams Up with Imprint for New Credit Card Kroger’s at it again, folks. They're rolling out a shiny new Mastercard, and it's not just any plastic—it’s powered by the AI-driven platform Imprint. Now, what does this mean for you and me? Well, if you're a frequent flyer at Kroger aisles, you might want to pay attention because this card’s offering point...

Varda Space's Dual Launch Signals Orbital Ambitions

It's not every day you see two commercial rockets heading to orbit on the same ride, but that's precisely what Varda Space Industries just pulled off. With the W-8 and W-9 vehicles blasting off together, Varda is positioning itself for a leap in orbital operations. They've hitched a ride aboard SpaceX's Transporter-18 mission, and this is more than just a double...

Athlete Threats: Public Info Fuels Security Risks

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

Hyundai's Record Q3 Sales: SUVs and Hybrids Lead

Hyundai's Drive to Record Q3 Sales When talking about market moves, Hyundai's recent figures speak louder than most quarterly bells. September 2026 marked a whirlwind of growth for Hyundai Motor America, reporting record-breaking sales numbers not just for the month, but for Q3 as a whole. With a 9% jump from September last year in total vehicle sales and a remarkable 3%...

Concrete Pipe: Foundation of Modern Infrastructure

Reinforced Concrete Pipes Hold Their Ground You know, it might not be the flashiest part of our infrastructure toolkit, but concrete pipe plays a mighty big role behind the scenes. Even in this age of shiny new tech and constantly evolving materials, the classic concrete pipe still packs a punch—especially when you demand something that'll last. Enter Stephanie Ward, a...

Nelson-Jameson Boosts Cold Storage in California Move

An Icy Boost for the West Coast Dairy Player Every now and then, a company gets its cold storage game just right. Nelson-Jameson has added fresh muscle to its Turlock facility in California, making waves with serious logistical upgrades. The company's dogged pursuit of better operational efficiency in dairy processing isn't just about bragging rights. It's plain old good...

SaponiQ Reinvents Body Care with Botanical Soap Bars

Breaking Through with Simple Innovation I'll be the first to say it's not every day you hear about a soap company trying to shake things up in body care like it’s a tech startup, but here’s SaponiQ taking a wild swing at it with their lineup of botanical cleansing bars. These things are whipped up in their own U.S.-based facility using some fancy cold-process...

Maternal Health Index: A New Tool With Big Ambitions

A Fresh Take on Maternal Health Today's all about the Heartland Forward's fresh tool, the Maternal Resiliency Index. It's making a splash at the 2026 Heartland Summit with a lot of promise on its shoulders. Backed by economists and health gurus like Emily Oster and Dr. Neel Shah, this index ain't your run-of-the-mill tool. It's here to shake the couch coins out of...

Ace Hardware Ups the Stakes with Rewards Days Event

Ace Hardware: Doubling Down with Rewards Ace Hardware's rolling out the red carpet for its loyal customers. Imagine this: exclusive deals on trusted brands and double points on purchases—an incentive any savvy shopper would jump at. From October 6 to 7, those in the Ace Rewards circle have the chance to nab some hefty savings and perks, a move that's more than just a...

Nukleus Launches Unified Platform for Athletes' Business

Leveling the Business Field for Athletes Athletes spend their lives fighting for every inch on the field, and now Nukleus is giving them the tools to hold ground off it. Why should they be the last ones to know their own business? Ashton Jeanty and Nukleus got tired of that narrative and kicked off a platform today with a real promise: putting an athlete's entire business...